| 产品描述: | BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K(ATP) channels |
| 靶点: |
BMS-191095 (50 μmol/L) 诱导 SD 大鼠血管平滑肌细胞 (VSM) 线粒体去极化。BMS-191095 (10-100 μmol/L) 剂量依赖性地诱导内皮剥脱脑动脉血管舒张。BMS-191095 (50 μmol/L) 增加了细胞钙火花的频率。BMS-191095 (0-1500 μM) 抑制胶原蛋白和凝血酶诱导的人血小板聚集,IC50 分别为 63.9 和 104.8 μM;PotassiumChannel |
| 体外研究: |
BMS-191095 (2.5 或 25 μg;脑室内灌注,缺血诱导前 30 分钟/60 分钟/24 小时,1次) 可减轻短暂性局灶性脑缺血对大鼠神经元的损伤。 Animal Model: Male Wistar rats with the induction of ischemia induced by middle cerebral artery occlusion (MCAO) Dosage: 2.5 or 25 μg Administration: Intraventricular infusion; 30 min/60 min/24 hours before the induction of ischemia, once Result: Reduced total infarct volume in rats with of pretreat dose of 25 mg and 24 h before MCA. Induced a rapid mitochondrial depolarization. |
| 体内研究: |
BMS-191095 (2.5 或 25 μg;脑室内灌注,缺血诱导前 30 分钟/60 分钟/24 小时,1次) 可减轻短暂性局灶性脑缺血对大鼠神经元的损伤。 |
| 参考文献: |
1. Katakam PV, et al. Diversity of mitochondria-dependent dilator mechanisms in vascular smooth muscle of cerebral arteries from normal and insulin-resistant rats. Am J Physiol Heart Circ Physiol. 2014 Aug 15;307(4):H493-503. 2. Cho MR, et al. BMS-191095, a cardioselective mitochondrial K(ATP) opener, inhibits human platelet aggregation by opening mitochondrial K(ATP) channels. Arch Pharm Res. 2005 Jan;28(1):61-7. 3. Mayanagi K, et al. The mitochondrial K(ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2007 Feb;27(2):348-55. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.446 ml |
12.229 ml |
24.457 ml |
| 5 mM |
0.489 ml |
2.446 ml |
4.891 ml |
| 10 mM |
0.245 ml |
1.223 ml |
2.446 ml |
| 50 mM |
0.049 ml |
0.245 ml |
0.489 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |